NICE Guidelines Set to Reduce Unnecessary Colonoscopies

By Staff Writer

September 21, 2023

A New Era for Colorectal Cancer Diagnosis

The National Institute for Health and Care Excellence (NICE) has released new guidance that could spare tens of thousands of people the need for a colonoscopy each year. The updated guidelines recommend offering people with signs or symptoms of colorectal cancer a home test using quantitative faecal immunochemical tests (FIT).

These tests, which measure the amount of blood in the faeces, could lead to faster diagnoses and fewer referrals to secondary care for unnecessary colonoscopies. This shift in approach would allow colonoscopy services to focus on the patients who need them most, improving both patient care and healthcare efficiency.

Positive Impact on the NHS and Patient Care

The North Tees and Hartlepool NHS Foundation Trust has already implemented the approach recommended by NICE. They found that they detected more cancers using fewer colonoscopies, which is beneficial for both patients and the NHS.

Mark Chapman, interim director of medical technology and digital evaluation at NICE, said the new recommendations could help around 100,000 people avoid unnecessary colonoscopies. Furthermore, it will free up waiting lists to diagnose those more likely to have colorectal cancer.

Genevieve Edwards, chief executive at Bowel Cancer UK, added that the new guidance would help GPs identify and refer the right patients for further testing quickly, potentially detecting bowel cancer at an earlier stage when it is more treatable and curable.

With colorectal cancer being the fourth most common cancer in the UK, these new guidelines represent a significant step forward in managing its diagnosis and treatment.

Reference url

Recent Posts

lenacapavir HIV prevention
      

Lenacapavir HIV Prevention: Approval and Access Strategy Updates

🌍 *Could a twice-yearly shot revolutionize HIV prevention?*
Gilead Sciences has submitted key applications to the EMA for lenacapavir, a groundbreaking HIV-1 capsid inhibitor designed for use as pre-exposure prophylaxis (PrEP). With promising trial results indicating a significant reduction in HIV infections, this innovation could enhance adherence to prevention strategies globally. Discover more about this game-changing development!

#SyenzaNews #globalhealth #healthcareInnovation

Africa health partnership
      

Strengthening Africa Health Partnership

🌍 Can collaboration redefine Africa’s health landscape?

A newly signed Memorandum of Understanding between Africa CDC and Global Health EDCTP3 promises to enhance health research, clinical trials, and pandemic preparedness on the continent. With a focus on training, local manufacturing, and equitable partnerships, this initiative aims to address pressing global health challenges while improving health outcomes across Africa.

Look into the details of this transformative partnership and its implications for the future of healthcare in the region!

#SyenzaNews #globalhealth #HealthcareInnovation

breast cancer Africa
    

Urgent Call for Enhanced Breast Cancer Africa Control Measures

🚨 Are we doing enough to tackle the imminent breast cancer crisis in Africa?

A recent WHO report reveals alarming trends, predicting that 135,000 women could succumb to breast cancer by 2040 unless urgent actions are taken. The report highlights critical gaps in healthcare infrastructure and capacity, emphasizing the need for investment in screening programs and professional training to improve outcomes across the continent.

Review the full article to explore the necessary steps towards reinforcing breast cancer control measures in Africa.

#SyenzaNews #globalhealth #oncology #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.